Veradigm (STU:AL21) Marketable Securities: €0.0 Mil (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AL21 Veradigm Inc STU:AL21
23 GF Score
Price €3.40
View Full Analysis

What is Veradigm Marketable Securities?

Veradigm STU:AL21 23 Marketable Securities is €0.0 Mil as of Dec. 2022. GuruFocus rates STU:AL21 with a GF Score™ of 23/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Veradigm's Marketable Securities for the quarter that ended in Dec. 2022 was €0.0 Mil.

Veradigm  (STU:AL21) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Veradigm Marketable Securities Related Terms

Veradigm Marketable Securities Historical Data

* Premium members only.

The historical data trend for Veradigm's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veradigm Marketable Securities Chart

Veradigm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Veradigm Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 May09 May10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:AL21
23GF Score
Veradigm Inc STU:AL21
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veradigm Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.0 Mil mean?
Veradigm (STU:AL21) has a Marketable Securities of €0.0 Mil as of Dec. 2022. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Veradigm and its competitors.
Is Veradigm's Marketable Securities too high?
Veradigm's current Marketable Securities is €0.0 Mil. Overall, Veradigm has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's Marketable Securities compare to WEAV and PHR?
Veradigm's Marketable Securities of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Healthcare Providers & Services company?
A good Marketable Securities depends on the Healthcare Providers & Services industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Veradigm and its competitors. Veradigm's current Marketable Securities is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (STU:AL21) has a current Marketable Securities of €0.0 Mil. The current Marketable Securities is €0.0 Mil. Veradigm's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Veradigm (STU:AL21), the current Marketable Securities is €0.0 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veradigm Business Description

Other Exchanges MDRX:USA
Address 222 Merchandise Mart Plaza, Suite 2024, Chicago, IL, USA, 60654
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
23GF Score

Get the complete analysis for STU:AL21

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.40
Price